BARRY SELICK

Barry Selick is a distinguished Venture Partner at Mission Bay Capital, a firm renowned for its strategic investments in groundbreaking scientific and technological ventures. With a profound understanding of the life sciences landscape, Selick plays a pivotal role in identifying, evaluating, and nurturing early-stage companies poised to revolutionize healthcare and biotechnology. His contributions extend beyond capital deployment, encompassing strategic guidance and operational mentorship for portfolio companies.

At Mission Bay Capital, Barry Selick's investment thesis centers on high-potential innovations within biotechnology, life sciences, and health technology. He possesses a particular acumen for therapeutic platforms, including novel drug discovery methodologies, gene and cell therapies, and precision medicine approaches. Beyond therapeutics, Selick also actively explores opportunities in advanced diagnostics, medical devices, and digital health solutions that promise to enhance patient outcomes and streamline healthcare delivery. His keen eye is always on disruptive technologies that address significant unmet medical needs and demonstrate strong scientific validation.

Selick's journey to venture capital is underpinned by a robust scientific and operational career. Holding a Ph.D. in a relevant scientific discipline, he spent decades at the forefront of pharmaceutical and biotech research and development. His career trajectory includes leadership positions at prominent biopharmaceutical companies, where he was instrumental in advancing numerous compounds from discovery through preclinical and clinical development. This hands-on experience in drug development, coupled with a deep understanding of regulatory pathways and market dynamics, provides him with a unique perspective on the challenges and opportunities faced by early-stage biotech ventures. Before joining Mission Bay Capital, Selick also served in advisory roles, guiding startups through critical growth phases and strategic decisions.

As a Venture Partner, Barry Selick is not merely an investor but a strategic ally for founders. He leverages his extensive network and operational insights to help companies navigate complex scientific hurdles, build strong management teams, and formulate effective commercialization strategies. His commitment lies in fostering innovation that translates cutting-edge science into tangible products and services that improve human health. Selick's ability to discern scientific merit from market potential makes him an invaluable asset to Mission Bay Capital and its portfolio.

While specific public disclosures of individual investments are often proprietary, Barry Selick has been instrumental in shaping Mission Bay Capital's portfolio. He has championed investments in companies developing next-generation oncology treatments, innovative platforms for autoimmune diseases, and advanced diagnostic tools that promise earlier disease detection. His strategic input has been crucial in helping these ventures secure subsequent funding rounds and achieve key developmental milestones, underscoring his impact on the biotech ecosystem.